Jefferies Upgrades AveXis (AVXS) to Buy

Jefferies upgraded AveXis (NASDAQ: AVXS) from Hold to Buy with a price target of $42.00.

Analyst Biren Amin commented, "AVXS reported updated SMA Type 1 data today in conjunction with earnings. The data continued to show no events in the therapeutic dose cohort and improving CHOP-INTEND scores. With this continued efficacy data along w/ positive feedback from an expert dinner suggesting that FDA may allow for a single-arm pivotal trial in SMA Type 1, we are upgrading to Buy."

For an analyst ratings summary and ratings history on AveXis click here. For more ratings news on AveXis click here.

Shares of AveXis closed at $34.80 yesterday.

You May Also Be Interested In

• New Street Research Upgrades Micron Technology (MU) to Buy
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
• Wells Fargo Upgrades FOX Corp. (FOXA) to Overweight